Literature DB >> 12424006

Role of peroxisome proliferator-activated receptor gamma and retinoid X receptor heterodimer in hepatogastroenterological diseases.

Laurent Dubuquoy1, Sébastien Dharancy, Sophie Nutten, Sven Pettersson, Johan Auwerx, Pierre Desreumaux.   

Abstract

The peroxisome proliferator-activated receptor gamma (PPARgamma) and its partner the retinoid X receptor (RXR) are two nuclear receptors that are expressed mainly in adipose tissue and which have a role in lipid metabolism and insulin sensitisation. New sites of PPARgamma/RXR expression have been described, especially in the intestinal tract, pancreas, and liver. Concomitantly, new functions have been attributed to this heterodimer in regulation of inflammation, by its inhibition of nuclear factor (NF)-kappaB and via stress-kinase pathways. These new sites and functions of PPARgamma/RXR have led to novel ideas about pathophysiology of different inflammatory digestive diseases and to development of innovative treatment strategies with PPARgamma activators.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12424006     DOI: 10.1016/S0140-6736(02)11395-X

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  56 in total

1.  Association of cartilage-specific deletion of peroxisome proliferator-activated receptor γ with abnormal endochondral ossification and impaired cartilage growth and development in a murine model.

Authors:  Roxana Monemdjou; Faezeh Vasheghani; Hassan Fahmi; Gemma Perez; Meryem Blati; Noboru Taniguchi; Martin Lotz; René St-Arnaud; Jean-Pierre Pelletier; Johanne Martel-Pelletier; Frank Beier; Mohit Kapoor
Journal:  Arthritis Rheum       Date:  2012-05

Review 2.  Exploring the emerging complexity in transcriptional regulation of energy homeostasis.

Authors:  Adelheid Lempradl; J Andrew Pospisilik; Josef M Penninger
Journal:  Nat Rev Genet       Date:  2015-10-13       Impact factor: 53.242

3.  Peroxisome proliferator-activated receptor-γ is downregulated in ulcerative colitis and is involved in experimental colitis-associated neoplasia.

Authors:  Xiaotan Dou; Junhua Xiao; Ziliang Jin; Ping Zheng
Journal:  Oncol Lett       Date:  2015-06-19       Impact factor: 2.967

4.  Role of peroxisome proliferator-activated receptors alpha and gamma in gastric ulcer: An overview of experimental evidences.

Authors:  Lekha Saha
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-11-06

5.  Creeping fat in Crohn's disease: travelling in a creeper lane of research?

Authors:  A Schäffler; H Herfarth
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

Review 6.  Mesenteric fat in Crohn's disease: a pathogenetic hallmark or an innocent bystander?

Authors:  Laurent Peyrin-Biroulet; Mathias Chamaillard; Florent Gonzalez; Elodie Beclin; Cecilia Decourcelle; Laurent Antunes; Jérôme Gay; Christel Neut; Jean-Frédéric Colombel; Pierre Desreumaux
Journal:  Gut       Date:  2006-09-06       Impact factor: 23.059

7.  Isotretinoin use and the risk of inflammatory bowel disease: a population-based cohort study.

Authors:  Raed O Alhusayen; David N Juurlink; Muhammad M Mamdani; Richard L Morrow; Neil H Shear; Colin R Dormuth
Journal:  J Invest Dermatol       Date:  2012-10-25       Impact factor: 8.551

Review 8.  Ste20-related proline/alanine-rich kinase: a novel regulator of intestinal inflammation.

Authors:  Yutao Yan; Didier Merlin
Journal:  World J Gastroenterol       Date:  2008-10-28       Impact factor: 5.742

Review 9.  The association between the peroxisome proliferator-activated receptor-gamma2 (PPARG2) Pro12Ala gene variant and type 2 diabetes mellitus: a HuGE review and meta-analysis.

Authors:  Hebe N Gouda; Gurdeep S Sagoo; Anne-Helen Harding; Jan Yates; Manjinder S Sandhu; Julian P T Higgins
Journal:  Am J Epidemiol       Date:  2010-02-23       Impact factor: 4.897

10.  PPARgamma, PTEN, and the Fight against Cancer.

Authors:  Rosemary E Teresi; Kristin A Waite
Journal:  PPAR Res       Date:  2008-12-14       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.